Jupiter Neurosciences, Inc. (JUNS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jupiter Neurosciences, Inc., a Delaware corporation and emerging growth company, on May 20, 2026. The report details the entry into a material definitive agreement for a registered direct offering of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered Direct Offering of Common Stock.
- Shares Issued: 7,142,858 shares.
- Offering Price: $0.28 per share.
- Gross Proceeds: Approximately $2.0 million.
- Placement Agent Fee: 7.0% of gross proceeds paid to D. Boral Capital LLC.
- Legal Expense Cap: Reimbursement of legal fees up to $75,000.
- Closing Date: Expected on or about May 21, 2026.
The filing does not provide specific data on revenue, profit, cash flow, margins, or existing debt levels as this is a transactional filing rather than a periodic financial report.
Material Changes and Restrictions
The Company entered into a Securities Purchase Agreement with investors and a Placement Agent Agreement with D. Boral Capital LLC. As part of the Purchase Agreement, the Company has agreed to restrictions on the issuance and sale of its Common Stock or Common Stock Equivalents for a 30-day period following the closing of the Offering.
Outlook, Risks, and Management Commentary
The Company issued a press release on May 20, 2026, announcing the pricing of the offering. The transaction is subject to the satisfaction of customary closing conditions. The filing includes standard representations, warranties, and indemnification provisions customary for such transactions. No specific forward-looking guidance or risk factors beyond standard transactional contingencies are detailed in this specific text.
Key Facts for Investor Verification
- Verify the final closing date and confirmation of the $2.0 million gross proceeds.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific terms regarding the 30-day issuance lock-up.
- Confirm the exact amount of placement agent fees and legal expenses deducted from the gross proceeds to determine net cash inflow.
- Check the Company's updated capitalization table to assess the dilution impact of the 7,142,858 new shares.